Introduction and hypothesisThe aim of this study was to compare preferences of patients with pelvic organ prolapse (POP) regarding their uterus between German- and Russian-speaking areas.MethodsSix urogynecologic tertiary referral centers participated in this prospective study: three centers from German-speaking countries and three from different regions of Russia. To assess the uterus-related preferences as well as the attitude toward hysterectomy versus uterus-sparing prolapse surgery, we developed a structured questionnaire that included 5-point Likert scales related to benefit of uterus (BOU) and benefit of not having uterus (BNU). Each scale consisted of 12 items (range of possible scores: 12–60). Finally, patients were asked if they preferred uterus removal or preservation when undergoing prolapse surgery.ResultsOne hundred and seventy-eight German-speaking and 206 Russian-speaking patients were included in the study. There was no significant difference in patients’ preference before undergoing POP surgery regarding uterus preservation versus hysterectomy between German- and Russian-speaking patients: 40% of German-speaking and 54% of Russian-speaking patients preferred to retain their uterus before undergoing POP surgery.Comparison of BOU mean scores showed a significant difference between groups: 20.6 ± 6.7 for German-speaking compared with 32.5 ± 9.1 for Russian-speaking patients (p < 0.01). The Russian-speaking group had significantly higher mean scores on domains sexuality, body image, and partnership of the BOU scale (2.6 ± 1.0 vs. 1.8 ± 0.9 for sexuality; 2.4 ± 1.1 vs. 1.5 ± 0.7 for body image, and 2.6 ± 0.9 vs. 1.6 ± 0.7 for partnership domains; p < 0.05).ConclusionsAlthough a large proportion of German- and Russian-speaking patients prefers uterus preservation when undergoing prolapse surgery, the uterus was more important for sexuality, partnership, and body image in Russian-speaking patients.Electronic supplementary materialThe online version of this article (10.1007/s00192-019-03918-9) contains supplementary material, which is available to authorized users.

No abstract

Aim. To assess the expression of vascular endothelial growth factor A for evaluating the functional state of the endometrium in women suffering from infertility and chronic endometritis.Materials and methods. Endometrium biopsy specimens obtained from 41 patients with uterine factor infertility (experimental group) were examined. A comparison group was composed of 39 women diagnosed with the “male factor” infertility exhibiting no infl ammatory processes of the reproductive organs. An endometrial biopsy was performed in both phases of the menstrual cycle: on days 8–10 of the follicular phase and on days 21–24 of the luteal phase. The expression of vascular endothelial growth factor receptors was evaluated on the basis of immunohistochemical staining of the biopsy specimens using monoclonal antibodies. The results of the immunohistochemical reaction were quantifi ed using the ImageJ software. A quantitative criterion — a stained area coeffi cient (per cent) representing the ratio of the immunohistochemical staining area to that of a biopsy specimen — was proposed for assessing the level of VEGF-A expression.Results. In the chronic endometritis group, the intensity of VEGF-A expression was found to be 1.4 times higher than that in the comparison group during the proliferation phase (p < 0.001). Expression values of the secretion phase were 1.9 times higher than those in the comparison group (p < 0.01).Conclusion. Chronic endometritis is characterized by an overexpression of VEGF-A by various endometrium cellular components. Interpretation of immunohistochemical stains using the method of computer morphometry allows quantitative indicators characterizing the intensity of angiogenesis marker expression in the endometrium during the menstrual cycle to be obtained. The level of VEGF-A expression can be used as an additional marker improving the quality of biopsy diagnostics in patients with infertility.

Introduction. One of the most significant issues that require close attention in the treatment and rehabilitation of patients with coronovirus infection is the analysis of the nutritional status of patients and the development of approaches to nutritional support for patients.Aim of study. Analysis of nutritional status of patients infected with COVID-19 and studying the effectiveness of specialized products dietary therapeutic and preventive nutrition during illness and recovery period.Materials and methods. A survey of 283 patients with mild and moderate severity was conducted. The survey showed a significant change in eating behavior in patients during the disease. To assess the effectiveness of nutritional support during the disease and during the recovery period, 36 individuals took a specialized product of dietary therapeutic and preventive nutrition “Detoxifying Kissel” LEOVIT DETOX daily after the diagnosis of COVID-19, both throughout the entire period of the disease, and within 2 weeks after the disease and going to work.Results and discussion. The survey showed the presence of a significant range of eating disorders in patients with coronavirus disease. It was found that in 90% of the respondents during the day, the main meal was 3 or more times. During the disease, the number of main meals decreased in 40% of individuals, and only in 4% of patients this figure increased. When using nutritional support with dietary therapeutic and prophylactic foods during the disease, patients noted a significant decrease in weakness and fatigue, temperature fluctuations, fears, anxiety, suspiciousness and other symptoms began to disappear. The continuation of the intake in the post-ovoid period of the use of nutritional support with the dietary therapeutic and preventive food product “Detoxifying Kissel” LEOVIT DETOX, contributes to a faster recovery of patients.Conclusion. The use of the dietary therapeutic and preventive food product “Detoxifying Kissel” LEOVIT DETOX is an effective method of nutritional support both during the disease and in the post-ovoid period. Long-term use of detoxification products (at least 3–6 months) after the disease is recommended.

No abstract